BBV152 prime cohort
comorbidity
A total of 190 participants were enrolled and 186 were randomized and received the study vaccine (92 SII-NVX-CoV2373 and 94 BBV152). Two participants withdrew consent before day 29. The safety population comprised 186 participants, both full analysis and per protocol populations comprised 184 participants (Fig. The demographic and baseline characteristics between the groups were comparable. Mean age was about 37 years and about 64% were males. About 15% participants had comorbidity. None of the participants was SARS CoV-2 RT-PCR positive. Median duration between two doses of prime series of BBV152 was 35 days and that between second dose of prime series and the booster dose was 298 days. The seropositivity for anti-S IgG and nAbs at baseline was comparable between the groups (Table 